Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2363-2370

  Goldberg, Richard M ^a   Reid, Joel M ^a   Ames, Matthew M ^a   Sloan, Jeff A ^a   Rubin, Joseph ^a   Erlichman, Charles ^a   Kuffel, Mary J ^a   Fitch, Thomas R ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAZARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; MELANOMA; NAUSEA; NEUTROPENIA; NOSE CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ADULT; ANTINEOPLASTIC AGENTS; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; METABOLIC CLEARANCE RATE; NAUSEA; NEOPLASMS; NEUTROPENIA;

EID: 0031418053     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Beisler, J. A., Abbasi, M. M., and Driscoll, J. S. The synthesis and antitumor activity of arabinosyl-5-azacytosine. Biochem. Pharmacol., 26: 2469-2472, 1977.
2. Beisler, J. A., Abbasi, M. M., and Driscoll, J. S. Synthesis and antitumor activity of 5-azacytosine arabinoside. J. Med. Chem., 22: 1230-1234, 1979.
3. Townsend, A., Leclerc, J. M., Dutschman, G., Cooney, D. A., and Cheng, D. C. Metabolism of 1-β-D-arabinosyl-5-azacytosine and incorporation into the DNA of human T-lymphoblastic cells (Molt-4). Cancer Res., 45: 3522-3528, 1985.
4. Grem, J. L., Shoemaker, D. D., Hoth, D. F., King, S. A., Plowman, J., Zaharko, D., Grieshaber, C. K., Harrison, S. D., Jr., Cradock, J. C., and Leyland-Jones, B. Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials. Invest. New Drugs, 5: 315-332, 1987.
5. Vesely, J., and Piskala, A. Mechanism of action of 1-β-D-arabinofuranosyl-5-azacytosine and its effects in L1210 leukemia cells. Neoplasma, 33: 3-10, 1986.
6. Driscoll, J. S., Johns, D. G., and Plowman, J. Comparison of the activity of arabinosyl-5-azacytosine, 1-β-D-arabinofuranoxylcytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia. Invest. New Drugs, 3: 331-334, 1985.
7. Zaharko, D. S., and Covey, J. M. Arabinosyl-5-azacytosine plasma kinetics and therapeutic response (L1210) in vitro and in vivo in mice. Invest. New Drugs. 3: 323-329, 1985.
8. Dalal, M., Plowman, J., Breitman, T. R., Schuller, H. M., del Campo, A. A., Vistica, D. T., Driscoll, J. S., Cooney, D. A., and Johns, D. G. Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties. Cancer Res., 46: 831-838, 1986.
9. Wallace, R. E., Lindh, D., and Durr, F. E. Arabinosyl-5-azacytosine (Ara-AC, fazarabine, NSC 281272) activity against human tumor xenografts. Proc. Am. Assoc. Cancer Res., 28: 307, 1987.
10. Glazer, R. I., and Knode, M. C. 1-β-D-Arabinosyl-5-azacytosine: cytocidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells. Mol. Pharmacol., 26: 381-387, 1984.
11. Stopper, H., Korber, C., Gibis, P., Spencer, D. L., and Caspary, W. J. Micronuclei induced by modulators of methylation: analogs of 5-azacytidine. Carcinogenesis (Lond.), 7: 1647-1650, 1995.
12. Division of Cancer Treatment, National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: National Cancer Institute, 1988.
13. Heideman, R. L., Roth, J. S., Ford, H., Jr., Kinard, R. D., Litterst, C. I., and Kelley, J. A. Reverse phase HPLC determination and murine pharmacokinetics of arabinosyl-5-azacytosine. J. Liq. Chromatogr., 12: 1613-1633, 1989.
14. Njissi, M. Testing the significance of Kendall's τ and Spearman's ρ. Psychol. Bull., 103: 235-237, 1988.
15. Bailey, H., Tutsch, K. D., Arzoomanian, R. Z., Tombes, M. B., Alberti, D., Bruggink, J., and Wilding, G. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. Cancer Res., 51: 1105-1108, 1991.
16. Surbone, A., Ford, H., Jr., Kelley, J. A., Ben-Baruch, N., Thomas, R. V., Fine, R., and Cowan, K. H. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272). Cancer Res., 50: 1220-1225, 1990.
17. Johnston, P. G., Kleiner, D., and Cowan, K. H. Fazarabine: a report of response in a patient with multiply relapsed embryonal cell carcinoma. Am. J. Clin. Oncol., 16: 34-37, 1993.
18. Amato, R., Ho, D., Schmidt, S., Krakoff, I. H., and Raber, M. Phase I trial of a 72-h continuous-infusion schedule of fazarabine. Cancer Chemother. Pharmacol., 30: 321-324, 1992.
19. Casper, E. S., Schwartz, G. K., and Kelson, D. P. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest. New Drugs, 10: 205-209, 1992.
20. Ben-Baruch, N., Denicoff, A. M., Goldspiel, B. R., O'Shaugnessy, J. A., and Cowan, K. H. Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer. Invest. New Drugs, 11: 71-74, 1993.
21. Hubbard, K. P., Daugherty, K., Ajani, J. A., Pazdur, R., Levin, B., and Abbruzzese, J. L. Phase II trial of fazarabine in advanced colorectal carcinoma. Invest. New Drugs, 10: 39-42, 1992.
22. Comoriano, J., Greene, M., Braich, T., Marschke, R., Colon-Otero, G., and Rubin, J. Intravenous fazarabine (arabinosyl-5-azacytosine, Ara-AC) for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 12: 356, 1993.
23. Walters, R. S., Theriault, R. L., Holmes, F. A., Hortobagyi, G. N., and Esparza, L. Phase II trial of fazarabine (ara-AC, arabinosyl-5-azacytosine) in metastatic breast cancer. Invest. New Drugs, 10: 43-44, 1992.
24. Kuebler, J. P., Metch, B., Schuller, D. E., Keppen, M., and Hynes, H. E. Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study. Invest. New Drugs, 9: 373-374, 1991.
25. Selby, G. B., Upchurch, C., Townsend, J., and Eyre, H. J. A Phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study. Cancer Chemother. Pharmacol., 34: 179-180, 1994.
26. Williamson, S. K., Crowley, J. J., Livingston, R. B., Panella, T. J., and Goodwin, J. W. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma ot the lung: a Southwest Oncology Group study. Invest. New Drugs, 13: 67-71, 1995.
27. Manetta, A., Blessing, J. A., and Look, K. Y. A Phase II study of fazarabine in patients with advanced ovarian cancer. Am. J. Clin. Oncol., 78: 156-157, 1995.
28. Heideman, R. L., Gillespie, A., Ford, H., Reaman, G. H., Balis, F. M., Tan, C., Sato, J., Ettinger, L. J., Packer, R. J., and Poplack, D. G. Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res., 49: 5213-5216, 1989.
29. Ho, D. H., Brown, N., Lin, J. R., Covington, W., Newman, R. A., Raber, M., Amato, R., Schmidt, S., and Krakoff, I. H. Clinical pharmacology of 1-β-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion. Drug Metab. Dispos., 19: 643-647, 1991.